MannKind (MNKD) FDA announcement summary

Introduction and purpose

• FDA approved Afrezza for pediatric patients aged six and older, marking a significant milestone for children and adolescents with diabetes.

• The approval fulfills a long-standing goal to provide an alternative to mealtime injections for young patients.

• The announcement aims to explain the clinical, commercial, and strategic implications of this approval.

Details of approval or decision

• Afrezza is now indicated for children six and older, covering about 95% of pediatric type 1 diabetes cases.

• The label expansion is based on clinical data demonstrating efficacy and safety in the pediatric population.

• The product will be available for $35 or less for patients under 23, regardless of insurance.

Impact on industry and stakeholders

• The approval positions Afrezza as the first non-injectable mealtime insulin for children in over a century.

• Pediatric endocrinologists and key institutions are being targeted for rapid adoption.

• The addressable market includes 360,000 patients aged 6-22, with potential revenue of $300M-$500M from pediatrics alone.

• The ADA standards now recommend inhaled insulin as an option at every patient visit.